Helga Raab

Genesys (United States) — United States

Medicine · Health Sciences

31h-index8.4kcitations78works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(65), Monoclonal and Polyclonal Antibodies Research(52), Cancer Treatment and Pharmacology(15), CAR-T cell therapy research(14), Click Chemistry and Applications(13)

Publications78 total

Data from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
2023Open Access
Figures S1-S4, Tables S1-S2 from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
2023Open Access
Data from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
2023Open Access
Figures S1-S4, Tables S1-S2 from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
2023Open Access
Supplementary Figure 3C-D from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
Supplementary Figure 2 from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
Data from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
2023Open Access
Supplementary Methods, Figure Legends 1-3, Tables 1A-B from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
Supplementary 1 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
2023Open Access
Supplementary Figure 1 from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
Data from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
Data from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
2023Open Access
Supplementary Figure 2 from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
Supplementary Figure 3A-B from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
supplemental figure legend from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
2023Open Access
Supplementary Methods, Figure Legends 1-3, Tables 1A-B from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
supplemental figure legend from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
2023Open Access
Supplementary Figure 3C-D from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
Supplementary 2 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
2023Open Access
Data from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Richard Vandlen(21), Paul Polakis(21), Sunil Bhakta(19), Jagath R. Junutula(18), Susan D. Spencer(16), Richard H. Scheller(14), Shang‐Fan Yu(13), Reina N. Fuji(13), Andrew G. Polson(13), Katherine R. Kozak(12), Mark X. Sliwkowski(11), Gail D. Lewis Phillips(11), Guangmin Li(10), Rachana Ohri(10), Kelly M. Flagella(8), Elaine Mai(8), Jay Tibbitts(8), Allen Ebens(8), John A. Flygare(8), Kathryn L. Parsons(7)